Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
Financial and Market intelligence
Fundamental & Alternative Datasets
Government & Defense
Banking & Capital Markets
Economy & Finance
Energy Transition & Sustainability
Technology & Innovation
Podcasts & Newsletters
Financial and Market intelligence
Fundamental & Alternative Datasets
Government & Defense
Banking & Capital Markets
Economy & Finance
Energy Transition & Sustainability
Technology & Innovation
Podcasts & Newsletters
29 Jan, 2021
By Tyler Udland
Zelis Healthcare Inc. has completed the repricing of its $1.485 billion covenant-lite first-lien term loan due September 2026 that priced tight of talk at L+350, with a 0% Libor floor and an issue price of par via a Morgan Stanley-led arranger group, according to sources. The transaction lowers the spread of the term loan from L+475, with a 0% floor. The borrowers are Zelis Payments Buyers Inc. and Zelis Cost Management Buyer Inc. Bedminster, N.J.-based Zelis Healthcare is a healthcare information technology company that provides healthcare claims and payment management services. Terms:
| Borrower | Zelis Healthcare |
| Issue | $1.485 billion first-lien term loan |
| UoP | Repricing |
| Spread | L+350 |
| LIBOR floor | 0% |
| Price | 100 |
| Tenor | September 2026 |
| YTM | 3.78% |
| Four-year yield | 3.78% |
| Call protection | 101 soft call reset for 6 months |
| Corporate ratings | B/B2 |
| Facility ratings | B/B2 |
| Recovery ratings | 3 |
| Financial covenants | None |
| Arrangers | MS/Antares/CS/DB/GS/Jeff/UBS |
| Admin agent | MS |
| Px Talk | L+375-400/0%/100 |
| Sponsor | Parthenon Capital/Bain Capital |
| Notes |